Amy Feldman
Concepts (240)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 31 | 2026 | 841 | 7.040 |
Why?
| | Organ Transplantation | 15 | 2026 | 258 | 5.360 |
Why?
| | Biliary Atresia | 12 | 2026 | 163 | 3.840 |
Why?
| | Vaccination | 17 | 2026 | 1443 | 3.760 |
Why?
| | Transplant Recipients | 13 | 2026 | 183 | 3.340 |
Why?
| | Vaccines, Attenuated | 5 | 2026 | 129 | 2.700 |
Why?
| | Cholestasis | 8 | 2025 | 217 | 2.470 |
Why?
| | Immunization | 5 | 2023 | 375 | 1.680 |
Why?
| | Living Donors | 7 | 2026 | 289 | 1.620 |
Why?
| | Vaccines | 6 | 2023 | 389 | 1.610 |
Why?
| | Pediatrics | 6 | 2026 | 1139 | 1.540 |
Why?
| | Viral Vaccines | 2 | 2025 | 107 | 1.540 |
Why?
| | Hospital Costs | 2 | 2026 | 130 | 1.410 |
Why?
| | Chickenpox Vaccine | 3 | 2026 | 76 | 1.220 |
Why?
| | Child | 45 | 2026 | 22979 | 1.200 |
Why?
| | Liver Failure, Acute | 2 | 2023 | 70 | 1.180 |
Why?
| | Infant, Newborn, Diseases | 2 | 2021 | 116 | 1.180 |
Why?
| | Immunocompromised Host | 5 | 2026 | 202 | 1.100 |
Why?
| | Gastroenterology | 2 | 2023 | 191 | 1.050 |
Why?
| | Hospitalization | 4 | 2026 | 2496 | 1.010 |
Why?
| | Measles | 2 | 2024 | 46 | 0.960 |
Why?
| | Liver Diseases | 4 | 2024 | 307 | 0.960 |
Why?
| | Immunosuppressive Agents | 7 | 2026 | 840 | 0.940 |
Why?
| | Chickenpox | 2 | 2024 | 84 | 0.940 |
Why?
| | Communicable Diseases | 2 | 2019 | 166 | 0.930 |
Why?
| | Infant | 21 | 2026 | 10194 | 0.890 |
Why?
| | Measles Vaccine | 1 | 2024 | 19 | 0.840 |
Why?
| | Rubella | 1 | 2023 | 23 | 0.780 |
Why?
| | Mumps | 1 | 2023 | 21 | 0.780 |
Why?
| | Adenoviridae Infections | 1 | 2023 | 20 | 0.750 |
Why?
| | Graft Survival | 9 | 2026 | 534 | 0.730 |
Why?
| | Child, Preschool | 16 | 2026 | 12016 | 0.720 |
Why?
| | Mobile Applications | 1 | 2025 | 199 | 0.720 |
Why?
| | DNA, Viral | 1 | 2024 | 357 | 0.710 |
Why?
| | Practice Patterns, Physicians' | 2 | 2025 | 1379 | 0.710 |
Why?
| | Humans | 65 | 2026 | 147293 | 0.700 |
Why?
| | Registries | 10 | 2026 | 2434 | 0.700 |
Why?
| | Bilirubin | 2 | 2019 | 102 | 0.680 |
Why?
| | Transplantation | 1 | 2021 | 33 | 0.670 |
Why?
| | Waiting Lists | 3 | 2026 | 268 | 0.670 |
Why?
| | Postoperative Complications | 5 | 2026 | 3022 | 0.670 |
Why?
| | Education, Medical, Graduate | 2 | 2023 | 568 | 0.650 |
Why?
| | Fellowships and Scholarships | 2 | 2023 | 357 | 0.650 |
Why?
| | Herpesvirus 3, Human | 1 | 2024 | 343 | 0.640 |
Why?
| | Graft Rejection | 6 | 2026 | 523 | 0.640 |
Why?
| | Kidney Transplantation | 3 | 2026 | 732 | 0.640 |
Why?
| | Spinal Muscular Atrophies of Childhood | 1 | 2020 | 20 | 0.620 |
Why?
| | Primary Graft Dysfunction | 1 | 2020 | 33 | 0.620 |
Why?
| | RNA, Viral | 1 | 2024 | 695 | 0.620 |
Why?
| | Motor Cortex | 1 | 2020 | 65 | 0.610 |
Why?
| | Neonatal Screening | 2 | 2019 | 185 | 0.610 |
Why?
| | Wrist | 1 | 2020 | 60 | 0.610 |
Why?
| | Cholagogues and Choleretics | 1 | 2019 | 5 | 0.590 |
Why?
| | Opportunistic Infections | 1 | 2019 | 47 | 0.580 |
Why?
| | Oligonucleotides | 1 | 2020 | 154 | 0.580 |
Why?
| | Nutritional Support | 1 | 2019 | 40 | 0.580 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2020 | 138 | 0.560 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2019 | 104 | 0.550 |
Why?
| | Societies, Medical | 3 | 2026 | 914 | 0.550 |
Why?
| | Digestive System Surgical Procedures | 1 | 2019 | 112 | 0.540 |
Why?
| | Postoperative Care | 1 | 2020 | 299 | 0.540 |
Why?
| | Patient Acceptance of Health Care | 1 | 2025 | 895 | 0.530 |
Why?
| | Genetic Therapy | 1 | 2020 | 317 | 0.530 |
Why?
| | Pyruvic Acid | 1 | 2017 | 51 | 0.490 |
Why?
| | Immunization Schedule | 1 | 2018 | 186 | 0.480 |
Why?
| | Cytomegalovirus Infections | 2 | 2023 | 210 | 0.480 |
Why?
| | Disease Outbreaks | 1 | 2020 | 420 | 0.480 |
Why?
| | Cross Infection | 1 | 2019 | 261 | 0.470 |
Why?
| | Mitochondrial Diseases | 1 | 2017 | 94 | 0.460 |
Why?
| | Retrospective Studies | 20 | 2026 | 17560 | 0.460 |
Why?
| | Lactic Acid | 1 | 2017 | 295 | 0.440 |
Why?
| | United States | 10 | 2025 | 16313 | 0.440 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2017 | 140 | 0.440 |
Why?
| | Adaptive Immunity | 2 | 2015 | 171 | 0.430 |
Why?
| | Healthcare Disparities | 1 | 2021 | 740 | 0.420 |
Why?
| | Surveys and Questionnaires | 6 | 2025 | 6164 | 0.420 |
Why?
| | Male | 24 | 2026 | 73950 | 0.410 |
Why?
| | Adolescent | 17 | 2026 | 22825 | 0.410 |
Why?
| | Treatment Outcome | 17 | 2026 | 11947 | 0.410 |
Why?
| | Rotavirus | 1 | 2013 | 21 | 0.400 |
Why?
| | Health Services Accessibility | 2 | 2021 | 1121 | 0.390 |
Why?
| | Rotavirus Infections | 2 | 2013 | 37 | 0.390 |
Why?
| | Female | 24 | 2026 | 80076 | 0.390 |
Why?
| | End Stage Liver Disease | 3 | 2026 | 95 | 0.380 |
Why?
| | Infant, Newborn | 7 | 2025 | 6543 | 0.380 |
Why?
| | Prognosis | 4 | 2026 | 4383 | 0.370 |
Why?
| | Follow-Up Studies | 4 | 2026 | 5476 | 0.370 |
Why?
| | Reoviridae Infections | 1 | 2012 | 54 | 0.350 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2020 | 1431 | 0.340 |
Why?
| | Hepatitis | 2 | 2021 | 43 | 0.330 |
Why?
| | Anemia, Aplastic | 2 | 2021 | 42 | 0.330 |
Why?
| | Health Status | 1 | 2016 | 839 | 0.320 |
Why?
| | Telemedicine | 1 | 2019 | 978 | 0.310 |
Why?
| | Immunity, Innate | 2 | 2013 | 840 | 0.300 |
Why?
| | Preoperative Period | 2 | 2020 | 150 | 0.300 |
Why?
| | Survival Rate | 4 | 2019 | 2110 | 0.300 |
Why?
| | Canada | 2 | 2023 | 435 | 0.280 |
Why?
| | B-Lymphocytes | 1 | 2013 | 878 | 0.260 |
Why?
| | Immunization Programs | 2 | 2021 | 194 | 0.260 |
Why?
| | Measles-Mumps-Rubella Vaccine | 1 | 2026 | 48 | 0.230 |
Why?
| | Cohort Studies | 4 | 2024 | 6099 | 0.230 |
Why?
| | Immunogenicity, Vaccine | 1 | 2026 | 40 | 0.230 |
Why?
| | Hypertension, Portal | 2 | 2017 | 67 | 0.230 |
Why?
| | Cholangitis, Sclerosing | 1 | 2026 | 61 | 0.220 |
Why?
| | Antibodies, Viral | 3 | 2024 | 687 | 0.220 |
Why?
| | Risk Assessment | 4 | 2022 | 3784 | 0.220 |
Why?
| | Organ Preservation | 1 | 2025 | 127 | 0.210 |
Why?
| | Child Health | 1 | 2026 | 154 | 0.210 |
Why?
| | Measles virus | 1 | 2024 | 21 | 0.210 |
Why?
| | Perfusion | 1 | 2025 | 252 | 0.210 |
Why?
| | Vaccination Coverage | 1 | 2025 | 106 | 0.200 |
Why?
| | Smartphone | 1 | 2025 | 107 | 0.200 |
Why?
| | Parents | 2 | 2025 | 1428 | 0.200 |
Why?
| | Vaccines, Combined | 1 | 2023 | 49 | 0.200 |
Why?
| | Health Care Surveys | 1 | 2025 | 538 | 0.190 |
Why?
| | Quality of Life | 1 | 2016 | 3246 | 0.190 |
Why?
| | Age Factors | 3 | 2026 | 3372 | 0.190 |
Why?
| | Hepatoblastoma | 1 | 2023 | 52 | 0.190 |
Why?
| | Stroke Rehabilitation | 1 | 2023 | 44 | 0.190 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2024 | 129 | 0.190 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1550 | 0.190 |
Why?
| | Alagille Syndrome | 1 | 2022 | 29 | 0.180 |
Why?
| | Glomerular Filtration Rate | 1 | 2026 | 765 | 0.180 |
Why?
| | Adenoviridae | 1 | 2023 | 199 | 0.180 |
Why?
| | Elasticity Imaging Techniques | 1 | 2022 | 59 | 0.180 |
Why?
| | Immunity, Humoral | 2 | 2013 | 119 | 0.170 |
Why?
| | Health Care Costs | 1 | 2025 | 428 | 0.170 |
Why?
| | Sarcoma | 1 | 2023 | 210 | 0.170 |
Why?
| | Incidence | 2 | 2019 | 2954 | 0.170 |
Why?
| | Malnutrition | 1 | 2021 | 87 | 0.160 |
Why?
| | Feasibility Studies | 1 | 2025 | 1147 | 0.160 |
Why?
| | Evoked Potentials, Motor | 1 | 2020 | 52 | 0.160 |
Why?
| | Prednisolone | 1 | 2020 | 67 | 0.150 |
Why?
| | Sarcopenia | 1 | 2021 | 92 | 0.150 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2013 | 415 | 0.150 |
Why?
| | Transcranial Magnetic Stimulation | 1 | 2020 | 67 | 0.150 |
Why?
| | Wrist Joint | 1 | 2020 | 73 | 0.150 |
Why?
| | Polymerase Chain Reaction | 1 | 2023 | 1046 | 0.150 |
Why?
| | Remission Induction | 1 | 2020 | 310 | 0.150 |
Why?
| | Case-Control Studies | 2 | 2024 | 3660 | 0.150 |
Why?
| | Heart Transplantation | 1 | 2026 | 682 | 0.150 |
Why?
| | Functional Laterality | 1 | 2020 | 241 | 0.150 |
Why?
| | Vaccination Refusal | 1 | 2020 | 61 | 0.150 |
Why?
| | Biomedical Research | 1 | 2026 | 723 | 0.140 |
Why?
| | Postoperative Period | 1 | 2020 | 351 | 0.140 |
Why?
| | Pilot Projects | 1 | 2024 | 1912 | 0.140 |
Why?
| | Movement | 1 | 2020 | 293 | 0.140 |
Why?
| | Early Diagnosis | 1 | 2019 | 254 | 0.130 |
Why?
| | Chronic Disease | 1 | 2024 | 1844 | 0.130 |
Why?
| | Electromyography | 1 | 2020 | 419 | 0.130 |
Why?
| | Morbidity | 1 | 2019 | 323 | 0.130 |
Why?
| | Immunization, Secondary | 1 | 2018 | 93 | 0.130 |
Why?
| | Treatment Refusal | 1 | 2018 | 99 | 0.130 |
Why?
| | Pandemics | 2 | 2025 | 1720 | 0.130 |
Why?
| | Survivors | 2 | 2023 | 528 | 0.130 |
Why?
| | Transplantation Immunology | 1 | 2017 | 29 | 0.130 |
Why?
| | Liver Neoplasms | 1 | 2023 | 787 | 0.120 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2017 | 23 | 0.120 |
Why?
| | Palivizumab | 1 | 2016 | 11 | 0.120 |
Why?
| | Tissue and Organ Procurement | 1 | 2020 | 350 | 0.120 |
Why?
| | Curriculum | 1 | 2023 | 1082 | 0.120 |
Why?
| | Statistics, Nonparametric | 1 | 2017 | 430 | 0.120 |
Why?
| | Glucocorticoids | 1 | 2020 | 537 | 0.110 |
Why?
| | Cost-Benefit Analysis | 1 | 2019 | 653 | 0.110 |
Why?
| | Guideline Adherence | 1 | 2020 | 590 | 0.110 |
Why?
| | Liver Failure | 1 | 2016 | 83 | 0.110 |
Why?
| | Enterostomy | 1 | 2015 | 7 | 0.110 |
Why?
| | Liver Cirrhosis, Biliary | 1 | 2015 | 15 | 0.110 |
Why?
| | Failure to Thrive | 1 | 2015 | 28 | 0.110 |
Why?
| | Cholangitis | 1 | 2015 | 22 | 0.110 |
Why?
| | Attitude to Health | 1 | 2018 | 431 | 0.110 |
Why?
| | Prospective Studies | 2 | 2024 | 8164 | 0.100 |
Why?
| | Preoperative Care | 1 | 2017 | 381 | 0.100 |
Why?
| | Liver | 4 | 2023 | 1916 | 0.100 |
Why?
| | Stroke | 1 | 2023 | 1287 | 0.100 |
Why?
| | Mycophenolic Acid | 2 | 2025 | 119 | 0.100 |
Why?
| | Adult | 3 | 2026 | 41405 | 0.100 |
Why?
| | Antigen-Presenting Cells | 1 | 2013 | 161 | 0.090 |
Why?
| | Risk Factors | 3 | 2026 | 11017 | 0.090 |
Why?
| | Constriction, Pathologic | 2 | 2025 | 252 | 0.090 |
Why?
| | Th1 Cells | 1 | 2013 | 139 | 0.090 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 742 | 0.090 |
Why?
| | Qualitative Research | 1 | 2020 | 1735 | 0.090 |
Why?
| | Attitude of Health Personnel | 1 | 2020 | 1220 | 0.090 |
Why?
| | Logistic Models | 1 | 2017 | 2142 | 0.080 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 2133 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1518 | 0.080 |
Why?
| | Sex Factors | 1 | 2017 | 2136 | 0.080 |
Why?
| | Portoenterostomy, Hepatic | 2 | 2023 | 43 | 0.080 |
Why?
| | Antibody Formation | 2 | 2022 | 288 | 0.080 |
Why?
| | Immunity, Cellular | 1 | 2012 | 280 | 0.080 |
Why?
| | Cardiovascular Diseases | 1 | 2022 | 2218 | 0.080 |
Why?
| | Biomarkers | 2 | 2022 | 4351 | 0.080 |
Why?
| | Flow Cytometry | 1 | 2013 | 1172 | 0.070 |
Why?
| | Prevalence | 2 | 2026 | 2889 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1598 | 0.070 |
Why?
| | Disease Models, Animal | 2 | 2013 | 4604 | 0.060 |
Why?
| | RNA, Messenger | 2 | 2024 | 2812 | 0.050 |
Why?
| | Delphi Technique | 1 | 2026 | 347 | 0.050 |
Why?
| | Consensus | 1 | 2026 | 476 | 0.050 |
Why?
| | Stakeholder Participation | 1 | 2024 | 89 | 0.050 |
Why?
| | Hypertension, Pulmonary | 1 | 2015 | 1977 | 0.050 |
Why?
| | Propensity Score | 1 | 2025 | 379 | 0.050 |
Why?
| | Endoglin | 1 | 2022 | 19 | 0.050 |
Why?
| | Matrix Metalloproteinase 7 | 1 | 2022 | 25 | 0.050 |
Why?
| | Feedback | 1 | 2023 | 181 | 0.050 |
Why?
| | Cytomegalovirus | 1 | 2023 | 172 | 0.040 |
Why?
| | Upper Extremity | 1 | 2023 | 114 | 0.040 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 137 | 0.040 |
Why?
| | Antibodies | 1 | 2024 | 398 | 0.040 |
Why?
| | Interleukin-8 | 1 | 2022 | 269 | 0.040 |
Why?
| | North America | 1 | 2022 | 307 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2022 | 289 | 0.040 |
Why?
| | Tacrolimus | 1 | 2021 | 196 | 0.040 |
Why?
| | Horses | 1 | 2021 | 229 | 0.040 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2022 | 223 | 0.040 |
Why?
| | Enteral Nutrition | 1 | 2021 | 218 | 0.040 |
Why?
| | Nutritional Status | 1 | 2021 | 353 | 0.040 |
Why?
| | Mice | 2 | 2013 | 18491 | 0.040 |
Why?
| | Recovery of Function | 1 | 2023 | 724 | 0.040 |
Why?
| | Animals | 3 | 2021 | 38410 | 0.030 |
Why?
| | Emotional Adjustment | 1 | 2017 | 18 | 0.030 |
Why?
| | Family Relations | 1 | 2017 | 90 | 0.030 |
Why?
| | Health Policy | 1 | 2017 | 405 | 0.020 |
Why?
| | Bile Ducts | 1 | 2013 | 68 | 0.020 |
Why?
| | Lymphocyte Depletion | 1 | 2013 | 133 | 0.020 |
Why?
| | Adoptive Transfer | 1 | 2013 | 200 | 0.020 |
Why?
| | Colorado | 1 | 2021 | 4591 | 0.020 |
Why?
| | Virus Diseases | 1 | 2013 | 218 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2013 | 914 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2013 | 1266 | 0.020 |
Why?
| | Young Adult | 1 | 2026 | 14437 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2017 | 2973 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2013 | 708 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2197 | 0.020 |
Why?
| | Autoimmunity | 1 | 2013 | 935 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 7173 | 0.010 |
Why?
| | Disease Progression | 1 | 2013 | 2890 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2013 | 2458 | 0.010 |
Why?
| | Pregnancy | 1 | 2013 | 7274 | 0.010 |
Why?
|
|
Feldman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|